Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study

OBJECTIVE: To evaluate the efficacy and safety of sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma (HCC) to provide a more effective first-line treatment for patients with advanced HCC. METHODS: This open-label, prospective, phase II study...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Dailong, Xu, Lu, Ji, Jinxing, Bao, Dan, Hu, Juan, Qian, Ying, Zhou, Yinjie, Chen, Zhuo, Li, Daojun, Li, Xiaopeng, Zhang, Xiaoling, Wang, Hao, Yi, Changjun, Shi, Menglu, Pang, Yaqi, Liu, Siqi, Xu, Xinhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459134/
https://www.ncbi.nlm.nih.gov/pubmed/36091003
http://dx.doi.org/10.3389/fimmu.2022.944062

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459134/
https://www.ncbi.nlm.nih.gov/pubmed/36091003
http://dx.doi.org/10.3389/fimmu.2022.944062

Ejemplares similares